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Malaria vaccines are considered amongst the most important modalities for potential elimination of malaria disease
and transmission. Research and development in this field has been an area of intense effort by many groups over
the last few decades. Despite this, there is currently no licensed malaria vaccine. Researchers, clinical trialists and
vaccine developers have been working on many approached to make malaria vaccine available.
African research institutions have developed and demonstrated a great capacity to undertake clinical trials in
accordance to the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) standards in the last
decade; particularly in the field of malaria vaccines and anti-malarial drugs. This capacity is a result of networking
among African scientists in collaboration with other partners; this has traversed both clinical trials and malaria
control programmes as part of the Global Malaria Action Plan (GMAP). GMAP outlined and support global strategies
toward the elimination and eradication of malaria in many areas, translating in reduction in public health burden,
especially for African children. In the sub-Saharan region the capacity to undertake more clinical trials remains small
in comparison to the actual need.
However, sustainability of the already developed capacity is essential and crucial for the evaluation of different
interventions and diagnostic tools/strategies for other diseases like TB, HIV, neglected tropical diseases and non-
communicable diseases. There is urgent need for innovative mechanisms for the sustainability and expansion of the
capacity in clinical trials in sub-Saharan Africa as the catalyst for health improvement and maintained.
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Every year approximately 250 million clinical malaria
cases are reported [1] with about one million deaths in
sub-Saharan Africa, mostly in children under five years
of age [2]. If children survive multiple infections due to
malaria, such exposure leads to semi-immunity that
limits the severity of the disease later in life. However,
this immunity wanes in the absence of continued exposure
to malaria. Additionally, pregnant women and newborns
have reduced immunity and, therefore, are vulnerable to
severe complications of malaria infection and disease with
poor outcome [3,4].
The currently available tools for the control of malaria
are largely, early diagnosis and prompt treatment of clin-
ical episodes with effective anti-malarial drugs. Other* Correspondence: gmwangoka@ihi.or.tz
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distribution, and reproduction in any mediumtools include the promotion and use of insecticide-
treated nets (ITNs) as well as limited use of indoor
residual spraying (IRS) in an integrated manner tailored to
the socio-ecological setting. An effective malaria vaccine
would greatly complement available control measures and
accelerate the efforts towards achieving the elimination
and eradication goal. The research and development
agenda is to develop vaccines that can serve as key com-
ponents of a future arsenal of tools to eradicate malaria
[5]. Current efforts to develop malaria vaccines are pri-
marily directed towards reducing the morbidity and mor-
tality that are associated with malaria and focus on
Plasmodium falciparum. Malaria Vaccine Roadmap [6]
has a strategic goal of developing a vaccine with 80% pro-
tective efficacy against P. falciparum by 2020.
However, if malaria vaccines are to contribute to
programmes for malaria elimination, they will need to
have an impact on malaria transmission. The strategiestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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used in concert with other malaria control interventions
to interrupt malaria transmission and eventually contrib-
ute to the eradication of this disease. Moverover, vaccine
development efforts need pay attention to Plasmodium
species other than P. falciparum, especially Plasmodium
vivax, if malaria eradication is to be achieved [5].
Recent years have witnessed considerable effort from
international organizations to support and finance differ-
ent malaria control strategies aimed at control and elim-
ination of malaria; these efforts include malaria vaccine
development. This has led to a robust pipeline of malaria
vaccine candidates in the last decade. Several African re-
search institutions took centre stage in the evaluation of
these candidates including the front runner, RTS,S. The
largest phase III malaria vaccine trial on RTS,S involving
16,000 children is underway in 11 research centers in
seven African countries. The initial results of the phase
III, RTS,S/AS01 has shown to reduce severe malaria by
approximately 50% in older age group of 5 to 17 months
and 36.6% in the young children ( 6–12 weeks)[7,8].
This paper discusses the need for more effective tools to
control and eliminate malaria, and the challenges, oppor-
tunities, and experiences encountered during evaluation of
malaria vaccine candidates in Africa. Such information is
useful for future product Research and Development
(R&D) and to inform stakeholders in planning and imple-
menting future vaccine and drug trials.Challenges in selecting suitable malaria vaccine
candidates
Identification of malaria vaccine candidates together
with the understanding of the pathogen disease mechan-
ism and host immune response interactions has been a
major challenge. This is because of the complex life
cycle of the parasite. Moreover, P. falciparum presents
numerous antigens that could feasibly be targets of pro-
tective responses. However, such antigens are most often
polymorphic, and even exhibit clonal variation through
differential multigene expression.
Despite these challenges, efforts have been made to
develop malaria vaccine candidates. As of December
2012, WHO updated the rainbow table spread sheet in-
dicating the number of vaccine candidate that are in
clinical phase development and those still in preclinical
phases [9].This is a great achievement in vaccine devel-
opment whereby more vaccine have advanced to the
clinical phase. However, this may also show inability to
predict protection induced by a particular candidate vac-
cine in early phases hence, substantially increasing the
risks of investment by forcing investigators to make “go”
decisions based on immune measures tested to decide if
the approach is promising in large scale trials [10].Challenges in the implementation plan for vaccine trials
The correlates of malaria immunity
Vaccines are probably the single most cost-effective pub-
lic health intervention, past, present and possibly future,
to control emerging and re-emerging infectious diseases.
A vaccine is given in order to stimulate the development
of adaptive immune responses to fight a particular pa-
thogen against which the vaccine has been developed.
Regardless of the success in the development of malaria
vaccines, there is still a lack of understanding of individ-
ual immunity against malaria. Since the work of Koch
on Java Island at the end of the 19th Century, which
showed that adults who survive malaria infection acquire
a highly effective immunity, the mechanisms involved
and how they operate remains partly unknown, although
the antibody that blocks the invasion of merozoites into
erythrocytes appears to play a crucial role [11].
Some work has been done to determine which protect-
ive antigens or epitopes can be used in the construction
of recombinant, subunit or synthetic malaria vaccines
[12-14]. Surrogate markers of antibody efficacy currently
rely on in vitro assays that are laborious and difficult to re-
produce, and it remains unclear if such in vitro assays are
predictive of functional immunity in humans due to the
lack of suitable animal model permissive for P. falciparum
[15]. The work leading to antibody-dependent cellular in-
hibition (ADCI) is an important cue in the case presented
in this commentary on the need of more human evidence
based hypothesis. This approach led to studies to correlate
clinical protection in an endemic population with the im-
mune responses to malaria vaccine candidates in develop-
ment and gave insights into the relative proportion of
cytophilic antibodies to non-cytophilic antibodies (the C:
NC ratio) as being the most important surrogate marker
of protection to date[16-18].
Currently, there are no clear correlates of immunity
against pre-erythrocytic and blood-stage parasites.
Immuno-assays can be validated only once a vaccine dem-
onstrates efficacy in a clinical trial. Once an immune cor-
relate for protection is identified, it can be used for
decision making in clinical development. Immunoepi-
demiological studies have demonstrated that immunity
against blood stage Plasmodium falciparum is associated
with the acquisition of anti-parasite antibodies of the cyto-
philic subclasses [19], and in particular IgG3 [18,20-26].
Recently, it has been shown that, there is an associ-
ation between the frequency of RTS,S/AS01E induced
(circumsporozoite protein) CSP-specific CD4+ T cells
and protection from clinical malaria, most strongly seen
for IFNc-IL2-TNF + CD4+ T cells. Furthermore, there
were significant interactions between CSP-specific TNF +
CD4+ T cell responses and anti-CSP antibodies induced
by RTS,S/AS01E vaccination. This interaction suggests
that the protection afforded by the combination of CD4+
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predicted by their sum [27].
RTS,S vaccine candidate induces high concentrations
and frequencies of antibodies and CD4+ T cells, respect-
ively, specific for circumsporozoite protein (CSP) [28,29].
Anti-CSP antibodies correlate with protection against in-
fection in malaria naïve adult challenge studies [28] and
field studies in young children [30], against clinical malaria
in trials with young children in Kenya/Tanzania [31] and in
Gabon/Ghana/Tanzania [32], but anti-CSP antibodies did
not correlate with protection against clinical malaria in a
trial with older children in Mozambique [33]. Anti-CSP
antibodies could protect by a variety of mechanisms
including complement activation, antibody dependent
cellular cytotoxicity, sporozoite neutralization, and/or FccR
mediated phagocytosis [34].
Immunologic analyses indicate that high titre anti-CS
IgG are most strongly associated with RTS,S-mediated
protection, with an important additive component from
CS-specific Th1 cells. One recent study highlighted a
correlation between CS-specific TNFa(+) CD4 (+) T cells
and reduced morbidity, which requires confirmation in
other studies [31]. The first results from the Phase 3 trial
were published and were in line with expectations from
the Phase 2 trials [7,35], expect for the young age group
which provided modest protection against malaria [8]. A
likely explanation for the lower vaccine efficacy among
infants is an age-dependent differential immune response
to the vaccine. This concept is supported by the lower
anti-circumsporozoite antibody titers observed in infants
as compared with titers in older children reported previ-
ously [7].
Infants may have mounted a lower immune response
than older children owing to coadministration of RTS,S/
AS01 with routine EPI vaccines, an inhibitory effect of
maternally derived anti-circumsporozoite antibodies, an
absence of priming with hepatitis B vaccine or with
P. falciparum infection, or the infant’s immature immune
system. Coadministration of RTS,S/AS01 with the penta-
valent vaccine and the oral poliovirus vaccine might have
resulted in immune interference and contributed to the
lower anti-circumsporozoite antibody titers in the younger
infants [8].
There are many lessons to be learned from the RTS,S
trials including the major contribution of sporozoite
challenge trials, the importance of adjuvant, dose and
schedule optimization [36].
In a Phase 2a experimental sporozoite challenge trial
in malaria non-immune Caucasian volunteers, vaccine
related partial but modest protection against sporozoite
challenge was observed in terms of a delay in time to
parasitaemia [37], although no sterile protection was ob-
served. A recently completed Phase 1b vaccine trial in
semi-immune Tanzanian adults and children confirmedthe safety and immunogenicity of the platform. In ad-
dition, an exploratory analysis showed a reduced incidence
of clinical episodes of malaria. As interesting as it is, this
requires confirmation in field efficacy studies [38].
Other vaccines based on irradiated sporozoites or gen-
etically modified attenuated sporozoites have provided
protection in challenge models [39]. Such whole organ-
ism attenuated vaccines may provide effective protection
against malaria and significantly reduce parasite trans-
mission. Over 1,000 bites by the irradiated mosquitoes
per volunteer were required for consistent protection
against challenge. Importantly, there have been no
breakthrough P. falciparum infections in volunteers im-
munized by sporozoites irradiated with > 120 Gray units.
Protection against challenge lasted for at least 42 weeks
(10 months) after the last immunization. Furthermore,
studies have shown that volunteers who are exposed to
infected non-irradiated mosquitoes while taking chlo-
roquine develop durable protection [40,41]. However,
considerable technological challenges in terms of manu-
facturing, formulation, and delivery of such attenuated
sporozoite vaccines need to be overcome [5].
As for vaccines that target the sexual stage of the para-
site, they do not aim to prevent illness or infection in the
vaccinated individual, but to prevent or decrease transmis-
sion of the parasite to new hosts. This ‘transmission-
blocking’ vaccine can be seen as a true altruistic vaccine
[12]. Previous clinical trials of sexual stage vaccines that
have been discontinued involve ookinete antigens Pfs25
from P. falciparum and Pvs25 from P. vivax. In both stud-
ies and in pre-clinical work by the same group there is a
consistent correlation between titre of anti-Pfs25 antibody
and membrane-feeding assay (MFA) activity [42].
Nonetheless, in the absence of surrogate measures of
protection conferred by these vaccines, probably the best
way to assess the effectiveness of a developed vaccine is
by conducting clinical trials in natural conditions. For a
vaccine to be effective, it must elicit the appropriate im-
mune responses that will protect the individual from fu-
ture infections or disease.
The understanding of the immune correlates will pro-
vide the missing piece of puzzle to improve the perform-
ance of RTS,S and to fully optimize other vaccine
candidates. The ongoing phase III RTS,S vaccine trial is
a unique opportunity, with African scientists playing a
central role in assessing not only efficacy of the vaccine,
but also its mode of action and correlate(s) of protec-
tion. Exploration of factors that might affect vaccine effi-
cacy, including the effect of maternal antibodies, the role
of immune interference by EPI vaccines, the effect of the
RTS,S/AS01 booster, and status with respect to previous
exposure to P. falciparum parasites, will provide crucial
information for the further development of this vaccine
and for other malaria vaccines under development [9].
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acity (resources both human and infrastructure) develop-
ment in the field of basic human immunology and systems
biology. It will further foster the GCP-ICH and good clin-
ical laboratory practice (GCLP) approaches through
standardization of approaches, methods and procedures.
Clinical trial end points
Suitable choice of the primary end points in the con-
trolled trials is critical for each phase of clinical develop-
ment of the vaccine. For example, the ongoing phase III
RTS,S malaria vaccine trial has well-defined and harmo-
nized end points. This allows comparability of the per-
formance of the same intervention in different locations,
age groups and over time at the same location [43].
The investigation of relationship between parasite
density and likelihood of clinical disease can help to de-
velop a model of specificity and sensitivity for end point
definition. Standardization of one method that might
have been developed during previous studies is desirable
for accuracy, precision and key to comparisons across tri-
als and intra-trial (different sites). Based on this, laboratory
procedures for malaria parasite quantification in RTS,S
trial has been harmonized across sites to ensure both
accuracy and to allow for comparability throughout the
trial [44]. This includes, for instance, similar standard op-
eration procedures (SOPs) for slide reading and interpret-
ation, a key determinant of study end point in a malaria
intervention trial [45].
Selection of the appropriate clinical trial efficacy end
points (e g, risk of developing a disease or severe dis-
ease) is of crucial importance and calls for standardized
protocols of malaria case definition for current and fu-
ture trials or studies adapted to the different levels of
care where the protocols will be applied (e g, dispensary
versus hospital). Similarly, phase IV trials will also re-
quire full standardization of other key end points, such
as health system factors or cost-effectiveness and cost-
benefit assessments.
Monitoring of malaria transmission intensity
The malaria control strategies implemented in many en-
demic areas have resulted in a decrease of malaria trans-
mission in many parts of Africa and elsewhere [46].
Despite these efforts, vulnerable children, under five
years of age, are still at risk of dying from malaria dis-
ease. This calls for the continued search for a malaria
vaccine, which could complement the existing integrated
control strategies. Being able to measure accurately
malaria transmission is a key factor for any control
programme, as well as measuring the impact of new
control tools as identified by the MalERA-process [47].
Concurrent assessment of malaria transmission intensity
during malaria vaccine trails is important in theinterpretation of efficacy results by providing accurate
information on the endemicity and seasonality of malaria
transmission. Accurate data on transmission will also
help in the design of phase IV studies, deployment of
the vaccine and subsequently effective surveillance-
response systems in order to be able to evaluate and
understand the relationship between transmission in-
tensity and health outcomes in a given area. Unfortu-
nately there is still a lack of appropriate methodological
approaches.
Data generated through microsimulation [48,49] pro-
posed an algorithm estimation of human infection rates
from the entomological inoculation rate (EIR). Infant
mortality rates decrease markedly when the EIR is re-
duced, probably largely because of prevention of indirect
mortality. It was also observed that reduction of expos-
ure to malaria during infancy is not reflected in in-
creased mortality at older ages, a concern of many who
think that good childhood protection programmes may
predispose to later susceptibility [48]. Modeling is only
one of the avenues to be pursued for quick and better
capturing transmission with changing levels of endem-
icity; new approaches involving biomarkers and particu-
larly serology needs to be explored [47]. However,
modeling cannot replace real-time monitoring of trans-
mission during studies.
Challenges and opportunities during implementation
Clinical care as benefit to the community
In Africa, clinical trials are usually conducted in commu-
nities with little or limited access to health care facilities
and even if health facilities are present they often suffer
from limited resources, such as personnel, infrastructure
and medical supplies. Although it is well established that
any trial, irrespective of trial outcome, will contribute to
a general improvement in the health infrastructure and
the care provided, sponsors are not readily willing to
cover the additional cost to support/improve the health
care of the community where trials are conducted des-
pite this being a real need. Investigators should make a
collaborative effort to develop a policy of supporting
health care for the community where trials are being
conducted and this policy should be communicated to
sponsors during the planning stage.
Increasing the effectiveness and efficiency of health
care services is important everywhere but particularly in
developing countries with limited resources [50]. Clinical
audits are an example of a useful tool in improving clin-
ical care that should be adopted by African investigators.
The provision of quality care is a key factor in the suc-
cess of clinical trials with regard to community accept-
ance, compliance and adherence to protocol. This
ensures that the trial execution changes positively the
health-seeking behavior of the community concerned.
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well grounded in the study community will impart long
lasting health benefits.
Follow-up and adherence to the study protocol
Adherence to the study protocol in clinical trials is the
essential prerequisite for both the investigators and the
study participants. Failure of safety evaluation by the in-
vestigators or loss of follow-up among study participants
obviously creates major setbacks in research findings.
Loss of follow-up can be due to many reasons (death, ill-
ness, worsened health, and refusal, withdrawal, side ef-
fects and general dissatisfaction by participants with
regard to trial conduct) [51]. A well-planned and
conducted informed consent at individual and commu-
nity level can substantially reduce withdrawals and losses
to follow up [52]. Participants may not comprehend all
the information provided in the informed consent due
to the poor consenting process or literacy status of the
participant or misinformation about research in the
community. Engaging the community and participants is
cited as an element for a successful retention of partici-
pants in a study. The establishment of community advis-
ory boards (CAB) to enhance community understanding
of study and procedures of research lead to mutual trust
and a sense of collective ownership [53-57] and have be-
come an integral part of studies with long follow-up pe-
riods. Sponsors and investigators should, therefore,
make efforts to enhance two-way communication with
communities to discuss issues that may be of concern to
both parties.
Modern technology has helped to overcome poor in-
frastructure in African trial settings. Participants can
now be reached through mobile phones to enable re-
search teams to ask parents the health status of their
children, remind them of pending visits and schedule
emergency care. A simple questionnaire can be used to
evaluate health status via mobile phones, which are
reachable throughout the year, even during rainy sea-
sons, and reduce the problem of loss to follow up due to
poor roads. Proper planning and risk analysis by the in-
vestigators and sponsors before implementation is the key
to successful evaluation of the vaccine within African
communities. Geo-referencing has become a key tool in
knowing the location potential of study participants, dis-
tance to health facilities and other physical landmarks that
are of interest to specific research. This technology, linked
to continuous demographic surveillance, provides an opti-
mal framework for planning and executing large studies,
but comes with additional costs for which sponsors have
to be prepared.
The sharing of new information regarding the vaccine
under investigation is necessary and another way of pro-
viding incentives for participants and an avenue forsharing both negative and positive research results that
are important for future trials, it also keeps participants
loyal to the investigator and vice versa.
Harmonization of the ethical review process
Given the diversity of ethical review committees (ERC)
in Africa, there is a high likelihood of diverse decisions if
the same study protocols are submitted to these com-
mittees, particularly in a growing number of multicentre
studies. However, the decision-making process of the in-
dividual countries and committees must be respected.
The need to harmonize ethical review processes is ur-
gent. Harmonization could first focus on procedural as-
pects of the ethical review process and subsequently
address substantive aspects of ethical review, which
could be more challenging than the former. A participa-
tory approach to include all interested stakeholders is
critical for harmonization to be acceptable to African
ERCs and also to be effective in terms of improving the
quality and timing of the review process without com-
promising on science. During the process, clear roles
and responsibilities of national ERCs in relation to insti-
tutional ERCs in countries where both national and in-
stitutional committees exist, should be stipulated and
agreed by all involved. The role of the committees
should be complementary rather than duplicative. Such
clarity would go a long way towards minimizing poten-
tial antagonism between national and institutional ERCs
of the same country [58].
Capacity building for the committee members is of
equal importance, as it is crucial that ethical committees
reviewing protocols are adequately knowledgeable about
all established national and international guidelines.
AMANET, was among Africa’s research NGOs, made an
effort to promote health research in Africa that meets
international scientific and ethical standards. AMANET
took a holistic approach to address infrastructural, hu-
man and financial resource needs of African research in-
stitutions [59]. For example, the Ifakara Health Institute
(IHI) Ethical Review Committee in Tanzania secured a
sub-grant from AMANET which was used to start a
two-way community engagement programme aimed at
conveying information about health research ethics to
the communities in one of its centres involved in clinical
trials, Bagamoyo [60]. The programme enhanced the
ERC’s and the researchers’ understanding of community
concerns and perceptions on health research [61,62].
This approach by the ERC of engaging communities to
complement efforts that may be made by researchers
could go a long way to encouraging participatory ap-
proach in health research so as to ensure that partici-
pants and their communities are treated as stakeholders
who should be kept informed about research conducted
on them.
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ducting clinical trials to test different investigational
products in African countries, there is a need to con-
sider establishing pre-IND meetings, where researchers
invite members of different ethical committees and regu-
latory authorities to discuss the possibility of conducting
a potential study in order to speed up the process before
investing on such trial.
The harmonization of procedures is inevitable to be
able to adequately support multicountry studies. This
will be more evident as product development takes root
in Africa with local scientists leading the development of
products that have to undergo different stages across dif-
ferent countries because none of the countries is
endowed with the capacity for all the processes to sup-
port product development.
Capacity building
Today, different vaccine candidates have advanced in
clinical trials (phase II to III). These vaccine candidates
are being evaluated in a variety of transmission and epi-
demiology settings so as to demonstrate efficacy across
the board. A great push for evaluation of new malaria
prevention tools in malaria-endemic settings created the
drive to strengthen clinical research capacity in Africa,
both in human and physical infrastructure.
In Bagamoyo, Tanzania, for example, the IHI-site has
been able to conduct the malaria vaccine trial through
the use of a new, well-equipped research laboratory, a
renovated paediatric ward and enhanced telecommuni-
cations, thanks to support from the INDEPTH-Malaria
Clinical Trials Alliance (MCTA) and MVI. The Swiss
Tropical and Public Health Institute has been the site
partner through the process from planning the trial facil-
ity to date. The site also managed to establish a quality
assurance team that provides internal quality monitoring
to ensure compliance to the protocol and site-standard
operation procedures in line with GCP requirements.
MCTA has been working in partnership with Malaria
Vaccine Initiative (MVI), and the Medicines for Malaria
Venture (MMV) to support clinical trials site in Africa
in various aspects. Bagamoyo clinical trial site is one
among other African sites that received support from
MCTA for personnel training, acquisition of equipment
and infrastructure upgrades to ensure the successful exe-
cution of clinical trials. MCTA has enabled African clin-
ical research sites to establish and equip laboratories with
state-of-the-art equipment, improve communication sys-
tems, database management, financial and managerial sys-
tems, including human resources management. Patient
care and management has also been improved through
the use of digital X-rays which enable the clinical team to
improve diagnostics accuracy and service, not only for trial
participants but also for the community at large [62].Providing scientists and medical staff with access to qual-
ity facilities and equipment/technologies helps to retain
highly trained personnel, this in turn contributes signifi-
cantly to the improvement of quality of health care ser-
vices at national level.
Moreover, to fast tract capacity development, clinical
trial scientists or trialists need to have a recognized,
viable career path or professional development in the
African region, as in Europe, USA and Asia. Conceptual-
izing a clinical question, developing an appropriate proto-
col and ultimately conducting the trial to answer that
question is a research discipline that requires training, ex-
perience and critical thinking. Availability of a critical mass
of skilled clinical trial coordinators, clinical trial auditors,
laboratory technicians, data managers, statisticians, clinical
research nurses, and clinical trial physicians and investiga-
tors will make the African research centers take a lead in
the design and execution of their own programmes [63].
Sustainability of the clinical trial centers
Presently, few clinical trial centers exist in Africa that
can conduct ICH-GCP clinical trials. To ensure optimal
evaluation of the growing number of malaria vaccine
and drug candidates, not forgetting other diseases that
are in the pipeline, the available capacity must be
strengthened and expanded. This will ensure sustainabil-
ity of the centers while making sure their relevance in
scientific research is maintained in the dynamic clinical
landscape. Knowledge in biomedical ethics is also
needed to ensure standards are applied throughout any
clinical development process of products using varied
technological innovations that become available, such as
genetic engineering and nanotechnology.
The conduct of clinical trials is complex - not only in
terms of products being tested, but also in balancing sci-
entific and ethical obligations to study populations. The
capacity to ethically review study protocols and provide
ethical oversight of clinical trials is a core component of
responsible research systems. Each country and major
institution involved in the conduct of clinical trials
should have adequate capacity to conduct such ethics re-
view. EDCTP through MARC project (Mapping of ethics
review and trial regulatory capacity in sub-Sahara Africa)
supported strengthening of the existing ethical review
capacity of health research responsible to conduct
EDCTP funded clinical trials throughout Africa [64].
Career development and job security are required to
attract and retain African scientists to ensure there is a
critical mass of competent, skilled personnel available to
support these centers in the long term.
Finally, there is need for investment in capacity devel-
opment to perform long-term follow up of trial subjects,
including phase IV studies, to provide the information
on the rare events that may occur following the use of
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in turn suggests that such trial sites be linked to a health
and demographic surveillance system such those found
on the INDEPTH network, to ensure optimal longer
term follow up of populations involved in studies. This
is going to be critical for safe and effective monitoring at
all levels. For example, the concept of evaluating RTS,S
in phase IV should be planned in advance and budgeted
for as part of the risk management plan at registration
with regulatory authorities. Phase IV for RTS,S will be a
breakthrough and will bring a lot of knowledge that
might have been missed in previous and ongoing malaria
vaccine evaluations. This will also expand the scope of
the already established INDEPTH Network Effectiveness
and Safety Surveillance (INESS) embedded within the
existing HDSS platforms in Mozambique, Tanzania,
Ghana and Burkina Faso.
Besides the elements of human, physical and social
(community involvement) capacity building, sustainabil-
ity of a trial centre will only be assured once the centre
develops a full trial portfolio that goes beyond a single dis-
ease aspect and single disease research programme, e g, a
mid- to long-term portfolio that includes basic science,
drug and vaccine trials, for example, malaria, TB and HIV,
neglected diseases, non-communicable diseases for differ-
ent population groups (infants, children, adults). This will
allow continuous participation of African scientists in
finding new approaches and solutions to African and glo-
bal health problems.
Outlook
There are several malaria vaccine candidates and the
majority of these vaccines are based on recombinant
proteins and over one-half consist of a single antigen [9].
With limited financial resources available to evaluate
these candidates, scientists have to prioritize or develop
more define selection criteria to select vaccine candi-
dates to trial. Also, there is a requirement for different
clinical trial phases to be planned in advance. For in-
stance, facilities to conduct challenge studies, preclinical
and phase I – where the experimental infection of
malaria-naive volunteers by the bite of Plasmodium fal-
ciparum-infected mosquitoes has been a preferred
means to test the protective effect of malaria vaccine and
drug candidates in malaria-naive volunteers, is not the
same as for phase IV. State-of-the-art facilities for clinical
care, laboratories, expertise in terms of personnel need a
proper budgeting and preparation prior to implementation.
A systematic, evidence-based approach for prioritizing
vaccine candidates would expedite the development of a
specific candidate. The criteria for selection of a promis-
ing vaccine will provide a clear pathway and promote
greater confidence among scientists and funders that in-
vestments are focused on the best candidates. Thisapproach could facilitate collaboration between African
scientists and pharmaceutical companies in the formula-
tion and development of vaccine candidates. Exchange
of expertise will allow African investigators to be in-
volved in protocol development and study design, even-
tually building confidence and the basis to participate in
phase I, which is usually conducted in developed coun-
tries. GSK Biologicals, Rixensart and Novartis has been
supporting fellowship programmes which offer oppor-
tunities within the malaria young African investigators/
clinicians to get on job training in various aspect of clin-
ical trials and vaccine development. These research
training programmes are aimed at developing sustain-
able partnerships with select scientific institutions in
emerging countries to further this endeavor [65]. The es-
tablishment of phase I and challenge units in malaria-
endemic countries will expedite product development and
allow screening of products early in the target population
allowing for optimization of the candidates before the
conduct of field trials. This will also ensure these centers
participate in the full breadth of product development.
Developments over the past decade, as well as the
number of successfully completed malaria drug and vac-
cine trials, clearly shows the active participation of Afri-
can scientists in African research centers in the
evaluation of new tools against diseases of poverty. This
should provide the framework for moving phase I and
challenge studies to the region and ultimately make
Africa a key player in developing innovative solutions to
alleviate Africa’s disease burden and spur development.
Additionally, researchers conducting clinical trials in
developing countries have ethical obligations beyond
those falling on researchers working in the developed
world, such as ensuring access to standards of care and
ensuring the rights of study participants are held as the
oversight systems are not well developed. No single pro-
fession, team, or country has a monopoly on wisdom.
Establishing partnerships will assure procedural fairness
and promote the ethical conduct of clinical trials in a
world characterized by grave inequities.Competing interests
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